Page 42 - GALENIKA MEDICAL JOURNAL

45. Gadelha MR, Gordon MB, Doknic M, Mezősi E, Tóth M, Randeva H, et al. 49. Bolanowski M, Adnan Z, Doknic M, Guk M, Hána V, Ilovayskaya I, et al.
ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Front Endocrinol (Lausanne). 2022 Feb 22;13:816426.
Paltusotine in Patients With Acromegaly. J Clin Endocrinol Metab. 2023
Apr 13;108(5):e148-e159.
46. Gadelha MR, Casagrande A, Strasburger CJ, Bidlingmaier M, Snyder Konflikt interesa: Nema
PJ, Guitelman MA, et al. Acromegaly Disease Control Maintained
After Switching From Injected Somatostatin Receptor Ligands to Oral Primljeno: 03.11.2024.
Paltusotine. J Clin Endocrinol Metab. 2024 Dec 18;110(1):228-37. Prihvaćeno: 18.11.2024.
47. Ding D, Mehta GU, Patibandla MR, Lee CC, Liscak R, Kano H, et al. Onlajn: 31. 12. 2024.
Stereotactic Radiosurgery for Acromegaly: An International Multicenter
Retrospective Cohort Study. Neurosurgery. 2019;84:717-25.
48. Kasuki L, Wildemberg LE, Gadelha MR. Management of endocrine
disease: Personalized medicine in the treatment of acromegaly. Eur J
Endocrinol. 2018 Mar;178(3):R89-R100.

40 DOI: 10.5937/Galmed2412075D